{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:51Z","timestamp":1790916831554,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T00:00:00Z","timestamp":1785628800000},"content-version":"vor","delay-in-days":213,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["2023YJY-55"],"award-info":[{"award-number":["2023YJY-55"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101356","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:46:04Z","timestamp":1785919564000},"page":"101356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["BRAF V600E Co-mutations predict aggressive clinicopathological features in Chinese patients with differentiated thyroid cancer: A multicenter cohort study"],"prefix":"10.1016","volume":"48","author":[{"given":"Jing","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songyan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101356_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/965212","article-title":"Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors","volume":"2013","author":"Pellegriti","year":"2013","journal-title":"J. Cancer Epidemiol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101356_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"10387","key":"10.1016\/j.ctarc.2026.101356_bib0003","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101356_bib0004","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1089\/thy.2018.0186","article-title":"Using the American thyroid association risk-stratification system to refine and individualize the American joint committee on cancer eighth edition disease-specific survival estimates in differentiated thyroid cancer","volume":"28","author":"Ghaznavi","year":"2018","journal-title":"Thyroid"},{"issue":"10387","key":"10.1016\/j.ctarc.2026.101356_bib0005","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ctarc.2026.101356_bib0006","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocr. Rev."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101356_bib0007","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers15020413","article-title":"Effect of having concurrent mutations on the degree of aggressiveness in patients with thyroid cancer positive for TERT promoter mutations","volume":"15","author":"Alohali","year":"2023","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101356_bib0008","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1038\/s41467-019-10680-5","article-title":"Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer","volume":"10","author":"Yoo","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101356_bib0009","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic alterations in thyroid cancer: biological and clinical insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101356_bib0010","first-page":"55","article-title":"Differentiated and anaplastic thyroid carcinoma: major changes in the American joint committee on cancer eighth edition cancer staging manual","volume":"68","author":"Perrier","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101356_bib0011","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.1365-2559.2011.03907.x","article-title":"Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance","volume":"59","author":"McCluggage","year":"2011","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101356_bib0012","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2017.74.5497","article-title":"Patient age-associated mortality risk is differentiated by BRAF V600E status in papillary thyroid cancer","volume":"36","author":"Shen","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101356_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/9959649","article-title":"Risk and prognostic factors for BRAFV600E mutations in papillary thyroid carcinoma","volume":"2022","author":"Wei","year":"2022","journal-title":"BioMed. Res. Int."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101356_bib0014","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/cen.13413","article-title":"Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis","volume":"87","author":"Vuong","year":"2017","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"10.1016\/j.ctarc.2026.101356_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153510","article-title":"Diffuse intrathyroidal dissemination of papillary thyroid carcinoma with no stromal fibrosis at presentation: a pattern of aggressive differentiated thyroid carcinoma","volume":"224","author":"Fang","year":"2021","journal-title":"Pathol. Res. Pract."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101356_bib0016","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/thy.2011.0261","article-title":"The associations between RAS mutations and clinical characteristics in follicular thyroid tumors: new insights from a single center and a large patient cohort","volume":"22","author":"Fukahori","year":"2012","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101356_bib0017","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0304-3835(96)04196-1","article-title":"p53 gene mutation in thyroid carcinoma","volume":"103","author":"Ho","year":"1996","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101356_bib0018","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/ijc.26228","article-title":"Reactivation of p53 mutants by prima-1 in thyroid cancer cells","volume":"130","author":"Messina","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101356_bib0019","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1001\/jamaoncol.2016.3288","article-title":"Mortality risk stratification by combining BRAF V600E and TERT promoter mutations in papillary thyroid cancer: genetic duet of BRAF and TERT promoter mutations in thyroid cancer mortality","volume":"3","author":"Liu","year":"2017","journal-title":"JAMa Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101356_bib0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00411-021-00904-y","article-title":"Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer","volume":"60","author":"Espenbetova","year":"2021","journal-title":"Radiat. Environ. Biophys."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101356_bib0021","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1210\/en.2006-0921","article-title":"RET\/PTC rearrangements and BRAF mutations in thyroid tumorigenesis","volume":"148","author":"Ciampi","year":"2007","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101356_bib0022","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.surg.2021.03.056","article-title":"Presence of TERT \u00b1 BRAF V600E mutation is not a risk factor for the clinical management of patients with papillary thyroid microcarcinoma","volume":"170","author":"Lee","year":"2021","journal-title":"Surgery."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101356_bib0023","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2026.101356_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1270796","article-title":"How do BRAFV600E and TERT promoter mutations interact with the ATA and TNM staging systems in thyroid cancer?","volume":"14","author":"Mukhtar","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ctarc.2026.101356_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.540238","article-title":"The coexistence of genetic mutations in thyroid carcinoma predicts histopathological factors associated with a poor prognosis: a systematic review and network meta-analysis","volume":"10","author":"Zhao","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101356_bib0026","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/cancers15020413","article-title":"Effect of having concurrent mutations on the degree of aggressiveness in patients with thyroid cancer positive for TERT promoter mutations","volume":"15","author":"Alohali","year":"2023","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101356_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.anndiagpath.2025.152578","article-title":"Characterizing thyroid carcinomas in the elderly: histological subtypes and TERT promoter mutation analysis based on the latest WHO classification","volume":"80","author":"Koh","year":"2026","journal-title":"Ann. Diagn. Pathol."},{"key":"10.1016\/j.ctarc.2026.101356_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2025.156112","article-title":"Clinicopathological and molecular characteristics of papillary thyroid carcinoma with BRAF V600E and TERT promoter co-mutations","volume":"272","author":"Liu","year":"2025","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101356_bib0029","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1200\/JCO.2014.56.8253","article-title":"Association between BRAF V600E mutation and recurrence of papillary thyroid cancer","volume":"33","author":"Xing","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101356_bib0030","doi-asserted-by":"crossref","first-page":"E1130","DOI":"10.1210\/jc.2013-4048","article-title":"TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer","volume":"99","author":"Liu","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101356_bib0031","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1530\/ERC-17-0562","article-title":"Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer","volume":"26","author":"Song","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101356_bib0032","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41388-023-02889-y","article-title":"Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids","volume":"43","author":"Lasolle","year":"2024","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101356_bib0033","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101356_bib0034","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/cancers13081932","article-title":"NTRK fusion genes in thyroid carcinomas: clinicopathological characteristics and their impacts on prognosis","volume":"13","author":"Pekova","year":"2021","journal-title":"Cancers. (Basel)"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002674?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002674?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:02:48Z","timestamp":1790913768000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002674"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":34,"alternative-id":["S2468294226002674"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101356","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF V600E Co-mutations predict aggressive clinicopathological features in Chinese patients with differentiated thyroid cancer: A multicenter cohort study","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101356"}}